{"id":"bpm31510-nanosuspension-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"BPM31510 is a pan-PI3K inhibitor designed to improve the bioavailability and tolerability of buparlisib through nanosuspension technology. By inhibiting PI3K across multiple isoforms, it disrupts the PI3K/AKT/mTOR pathway, which is frequently hyperactivated in cancer cells. The nanosuspension formulation aims to enhance drug delivery and reduce gastrointestinal toxicity associated with the parent compound.","oneSentence":"BPM31510 is a nanosuspension formulation of buparlisib that inhibits phosphatidylinositol 3-kinase (PI3K) to block tumor cell proliferation and survival signaling.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:57:26.887Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced solid tumors (Phase 2 development)"}]},"trialDetails":[{"nctId":"NCT04752813","phase":"PHASE2","title":"A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)","status":"ACTIVE_NOT_RECRUITING","sponsor":"BPGbio","startDate":"2022-08-22","conditions":"Glioblastoma, Glioblastoma Multiforme","enrollment":50},{"nctId":"NCT02650804","phase":"PHASE2","title":"BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients","status":"COMPLETED","sponsor":"BPGbio","startDate":"2016-07-06","conditions":"Pancreatic Cancer","enrollment":45},{"nctId":"NCT01957735","phase":"PHASE1","title":"BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors","status":"COMPLETED","sponsor":"BPGbio","startDate":"2013-10","conditions":"Metastatic Cancer, Cancer, Solid Tumor","enrollment":97},{"nctId":"NCT04999488","phase":"EARLY_PHASE1","title":"Impact of Orally Administered BPM31510 on Mitochondrial Energetics in Older Adults With Sarcopenia","status":"WITHDRAWN","sponsor":"AdventHealth Translational Research Institute","startDate":"2023-12","conditions":"Sarcopenia","enrollment":""},{"nctId":"NCT03020602","phase":"PHASE1","title":"BPM31510 in Treating Patients With Recurrent High-Grade Glioma Previously Treated With Bevacizumab","status":"COMPLETED","sponsor":"Seema Nagpal","startDate":"2017-01-04","conditions":"Gliosarcoma, Recurrent Glioblastoma, Astrocytoma of Brain","enrollment":12},{"nctId":"NCT02793960","phase":"PHASE1","title":"Topical BPM31510 3.0% Cream in Patients With Epidermolysis Bullosa","status":"COMPLETED","sponsor":"Shasa Hu","startDate":"2016-08-10","conditions":"Epidermolysis Bullosa","enrollment":11},{"nctId":"NCT03002935","phase":"PHASE1","title":"A Safety Study of Orally Administered BPM31510 in Healthy Subjects","status":"COMPLETED","sponsor":"BPGbio","startDate":"2017-01","conditions":"Healthy","enrollment":25},{"nctId":"NCT02486055","phase":"PHASE1","title":"A Safety Study of Orally Administered BPM31510 in Healthy Subjects","status":"COMPLETED","sponsor":"BPGbio","startDate":"2015-11","conditions":"Healthy","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ubidecarenone, USP"],"phase":"phase_2","status":"active","brandName":"BPM31510 Nanosuspension Injection","genericName":"BPM31510 Nanosuspension Injection","companyName":"BPGbio","companyId":"bpgbio","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BPM31510 is a nanosuspension formulation of buparlisib that inhibits phosphatidylinositol 3-kinase (PI3K) to block tumor cell proliferation and survival signaling. Used for Advanced solid tumors (Phase 2 development).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}